GlassScriptPhysician profile
Jesty George
NPI 1922633874
$11,410.54
in general payments reported to CMS, 2019-2025
39 companies · $3,338 in 2025
The $3,338 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,672 · 2023: $2,492 · 2024: $3,908 · 2025: $3,338.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,707 · Honoraria: $23.19 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,707.20 |
| Honoraria | $23.19 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,915.65 | 2022-2025 | |
| Ucb, INC. | $1,113.37 | 2022-2025 | Rystiggo, Briviact, Fintepla |
| Novartis Pharmaceuticals Corporation | $930.45 | 2022-2025 | |
| Pfizer INC. | $905.03 | 2023-2025 | |
| Sk Life Science, INC. | $579.90 | 2022-2025 | |
| Neurocrine Biosciences, INC. | $561.17 | 2022-2025 | Ingrezza, Ongentys |
| Lundbeck LLC | $384.85 | 2023-2025 | Vyepti, Rexulti |
| Eisai INC. | $341.30 | 2022-2025 | |
| Biogen, INC. | $323.85 | 2023-2025 | Vumerity, Tysabri, Plegridy |
| Acadia Pharmaceuticals INC | $311.30 | 2022-2025 | Nuplazid |
| Emd Serono, INC. | $307.39 | 2023-2025 | Mavenclad |
| Lilly USA, LLC | $299.83 | 2022-2025 | Amyvid, Kisunla, Emgality |
| Allergan, INC. | $288.62 | 2022 | |
| Genentech USA, INC. | $245.62 | 2022-2025 | Ocrevus Zunovo, Ocrevus |
| Amneal Pharmaceuticals LLC | $199.90 | 2022-2025 | Rytary, Crexont |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesty George listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.